AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Medicare expansion boosts diagnostic reach
- FebriDx now covered by 55% of US Medicare
- Lumos eyes full national adoption
Lumos Diagnostics (ASX:LDX) has achieved a major milestone in its US commercialization efforts, securing additional Medicare reimbursement coverage for its flagship FebriDx point-of-care diagnostic test. The company announced that two more Medicare Administrative Contractors (MACs)—First Coast Service Options (FCSO) and Noridian Healthcare Solutions—have granted reimbursement status at a rate of US$41.38 per test, effective retroactively from April 1, 2025.
This update marks a significant expansion in access to FebriDx, which is now covered by four of the seven MACs in the United States. These four contractors collectively represent more than 55% of the country’s Medicare payment coverage, positioning Lumos Diagnostics—an ASX healthcare stock—for broader clinical adoption in the critical US healthcare market.
FebriDx is designed as a rapid diagnostic solution that helps healthcare providers differentiate between bacterial and viral respiratory infections at the point of care. This supports faster clinical decision-making and better-targeted treatments, which can help reduce unnecessary antibiotic prescriptions and improve patient outcomes.
The broader Medicare coverage not only expands FebriDx’s reach but also enhances its credibility as a valuable tool in outpatient care pathways. The US Medicare system, known for its stringent reimbursement criteria, typically serves as a benchmark for both private insurers and other national health systems. Therefore, gaining recognition from a majority of MACs is a major validation of FebriDx’s clinical and economic value.
According to Lumos Diagnostics' Managing Director Doug Ward, the recent developments underscore the company’s focus on integrating FebriDx into clinical workflows across the country. Ward highlighted that Lumos remains actively engaged with the remaining three MACs and is also pursuing partnerships with private insurers to drive nationwide access. These steps are crucial in transforming FebriDx from a niche product to a mainstream diagnostic solution across the US healthcare ecosystem.
With the support of Medicare and a clear roadmap for broader coverage, Lumos Diagnostics is now strategically placed to deepen its market penetration. This milestone also signals the company’s ongoing commitment to innovation in healthcare diagnostics, offering tools that align with the industry's push for faster, more accurate, and cost-effective patient care.
As Lumos continues to gain traction in the US, stakeholders will be watching closely for future coverage expansions that could further solidify FebriDx’s place in modern healthcare settings.
